• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

酪氨酸激酶抑制剂进展后再治疗：选择与挑战。

Tyrosine kinase inhibitors re-treatment beyond progression: choice and challenge.

机构信息

1 Department of Gerontology, Chengdu Military General Hospital, Chengdu 610083, China ; 2 Department of Oncology, the People's Hospital of Bishan County, Bishan, Chongqing 402760, China.

出版信息

J Thorac Dis. 2014 Jun;6(6):595-7. doi: 10.3978/j.issn.2072-1439.2014.04.36.

DOI:10.3978/j.issn.2072-1439.2014.04.36
PMID:24976979
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4073393/
Abstract

Tyrosine kinase inhibitors (TKIs) are highly effective agents for the treatment of lung cancer which harbors activated gene mutation. However, for patients with failure of TKI, TKI re-treatment beyond progression (TRBP) is still a potential option that has been proven by many literatures. In this review, we summarize the clinical evidence of TRBP and discuss the potential mechanisms to overcome TKI-acquired resistance.

摘要

酪氨酸激酶抑制剂（TKIs）是治疗携带激活基因突变的肺癌的高效药物。然而，对于 TKI 治疗失败的患者，TKI 后进展（TRBP）再治疗仍然是一个潜在的选择，这已被许多文献证明。在这篇综述中，我们总结了 TRBP 的临床证据，并讨论了克服 TKI 获得性耐药的潜在机制。

相似文献

1
Tyrosine kinase inhibitors re-treatment beyond progression: choice and challenge.酪氨酸激酶抑制剂进展后再治疗：选择与挑战。
J Thorac Dis. 2014 Jun;6(6):595-7. doi: 10.3978/j.issn.2072-1439.2014.04.36.
2
Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.克唑替尼联合或不联合 EGFR-TKI 治疗 EGFR 突变型 NSCLC 患者 EGFR-TKI 治疗失败后获得性 MET 扩增：一项多中心回顾性研究。
J Transl Med. 2019 Feb 21;17(1):52. doi: 10.1186/s12967-019-1803-9.
3
Strategies to Improve Outcomes of Patients with EGRF-Mutant Non-Small Cell Lung Cancer: Review of the Literature.改善表皮生长因子受体突变型非小细胞肺癌患者结局的策略：文献复习。
J Thorac Oncol. 2016 Feb;11(2):174-86. doi: 10.1016/j.jtho.2015.10.002. Epub 2015 Dec 19.
4
Clinical strategies for acquired epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small-cell lung cancer patients.非小细胞肺癌患者获得性表皮生长因子受体酪氨酸激酶抑制剂耐药的临床策略
Oncotarget. 2017 Aug 4;8(38):64600-64606. doi: 10.18632/oncotarget.19925. eCollection 2017 Sep 8.
5
Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors.表皮生长因子受体酪氨酸激酶抑制剂治疗的持续进行可延长对EGFR酪氨酸激酶抑制剂获得性耐药的非小细胞肺癌的疾病控制时间。
Oncotarget. 2015 Sep 22;6(28):24904-11. doi: 10.18632/oncotarget.4570.
6
Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).优化表皮生长因子受体（EGFR）突变阳性非小细胞肺癌（NSCLC）中酪氨酸激酶抑制剂（TKI）的治疗顺序。
Lung Cancer. 2019 Nov;137:113-122. doi: 10.1016/j.lungcan.2019.09.017. Epub 2019 Sep 23.
7
Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy.表皮生长因子受体（EGFR）突变的非小细胞肺癌在一线酪氨酸激酶抑制剂治疗中出现疾病进展时的优化管理。
Lung Cancer. 2017 Aug;110:7-13. doi: 10.1016/j.lungcan.2017.05.009. Epub 2017 May 11.
8
Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.人非小细胞肺癌中表皮生长因子受体-酪氨酸激酶抑制剂获得性耐药的当前机制及更新的治疗策略
J Cancer Res Ther. 2016 Dec;12(Supplement):C131-C137. doi: 10.4103/0973-1482.200613.
9
The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma.T790M突变在EGFR突变的晚期肺腺癌患者EGFR-TKI再挑战治疗中的作用。
Oncotarget. 2017 Jan 17;8(3):4994-5002. doi: 10.18632/oncotarget.14007.
10
T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients.T790M 突变与晚期 NSCLC 患者在 EGFR-TKI 治疗进展后更好的疗效相关。
Lung Cancer. 2014 Jun;84(3):295-300. doi: 10.1016/j.lungcan.2014.03.011. Epub 2014 Mar 15.

引用本文的文献

1
Continued gefitinib retreatment beyond progression in patients with advanced non-small cell lung cancer harboring sensitive mutations.对于携带敏感突变的晚期非小细胞肺癌患者，在疾病进展后继续使用吉非替尼进行再治疗。
J Int Med Res. 2020 Oct;48(10):300060520955030. doi: 10.1177/0300060520955030.

本文引用的文献

1
Re-administration after the failure of gefitinib or erlotinib in patients with advanced non-small cell lung cancer.晚期非小细胞肺癌患者在吉非替尼或厄洛替尼治疗失败后的再次治疗。
J Thorac Dis. 2013 Aug;5(4):400-5. doi: 10.3978/j.issn.2072-1439.2013.07.28.
2
Clinical response to crizotinib retreatment after acquisition of drug resistance.获得耐药性后对克唑替尼再治疗的临床反应。
J Clin Oncol. 2013 Jul 1;31(19):e322-3. doi: 10.1200/JCO.2012.46.4305. Epub 2013 May 28.
3
Re-challenge treatment of small-molecular inhibitors in NSCLC patients beyond progression.非小细胞肺癌患者疾病进展后小分子抑制剂的再激发治疗。
J Thorac Dis. 2012 Dec;4(6):647-9. doi: 10.3978/j.issn.2072-1439.2012.10.14.
4
Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer.表皮生长因子受体酪氨酸激酶抑制剂失败的临床模式及晚期非小细胞肺癌的后续管理。
Lung Cancer. 2013 Jan;79(1):33-9. doi: 10.1016/j.lungcan.2012.09.016. Epub 2012 Oct 15.
5
First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial.一线厄洛替尼治疗不适合化疗的晚期非小细胞肺癌患者（TOPICAL）：一项双盲、安慰剂对照、3 期临床试验。
Lancet Oncol. 2012 Nov;13(11):1161-70. doi: 10.1016/S1470-2045(12)70412-6. Epub 2012 Oct 16.
6
Epidermal growth factor receptor tyrosine kinase inhibitors beyond progressive disease: a retrospective analysis for Japanese patients with activating EGFR mutations.表皮生长因子受体酪氨酸激酶抑制剂超越进展期疾病：一项针对日本激活型 EGFR 突变患者的回顾性分析。
J Thorac Oncol. 2012 Nov;7(11):1722-7. doi: 10.1097/JTO.0b013e31826913f7.
7
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.ALK 阳性非小细胞肺癌患者中克唑替尼的活性和安全性：来自一项 I 期研究的更新结果。
Lancet Oncol. 2012 Oct;13(10):1011-9. doi: 10.1016/S1470-2045(12)70344-3. Epub 2012 Sep 4.
8
Should Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Be Continued beyond Progressive Disease?表皮生长因子受体-酪氨酸激酶抑制剂在疾病进展后是否应继续使用？
Case Rep Oncol. 2011 Sep;4(3):470-4. doi: 10.1159/000332758. Epub 2011 Sep 20.
9
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.克唑替尼治疗携带 ALK 基因重排的晚期非小细胞肺癌患者的总生存影响：一项回顾性分析。
Lancet Oncol. 2011 Oct;12(11):1004-12. doi: 10.1016/S1470-2045(11)70232-7. Epub 2011 Sep 18.
10
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.获得性 EGFR 抑制剂耐药的肺癌的基因和组织学演变。
Sci Transl Med. 2011 Mar 23;3(75):75ra26. doi: 10.1126/scitranslmed.3002003.